A model to estimate the dose to tumour following intracavity administration of radioimmunoconjugates to patients with malignant gliomas

British Journal of Radiology

Volumn 70, Issue NOV., 1997, Pages 1152-1161

  Hopkins, K ^a   Papanastassiou, V ^b   Zananiri, F A F ^c   Kemshead, J T ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IODINE 131; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; YTTRIUM 90;

ARTICLE; DOSIMETRY; GLIOBLASTOMA; HUMAN; MODEL;

EID: 0030844199     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.70.839.9536907     Document Type: Article

References (24)

1. Courtenay-Luck NS, Epenetos AA, Moore R. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Research 1986;46:6489-93.
2. Pectasides D, Steward S, Courtenay-Luck N, Rampling R, Munro AJ, Krausz T, et al. Antibody-guided irradiation of malignant pleural and pericardial effusions. Br J Cancer 1986;53:727-32.
3. Epenetos AA, Courtenay-Luck N, Snook SJ. Antibody guided irradiation of advanced ovarian carcinoma with intra-peritoneally administered radiolabelled monoclonal antibodies. J Clin Oncol 1987;12:1890-9.
4. 131I labelled MoAbs. Int J Radiat Oncol 1989;16:405-13.
5. Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, et al. Intraperitoneal Yttrium-90 labelled MoAb in ovarian cancer. J Clin Oncol 1990;8:1941-50.
6. 131I monoclonal antibodies in the therapy of leptomeningeal tumours. Cancer 1988;61:857-68.
7. Pizer BL, Papanastassiou V, Hancock J, Cassano W, Coakham HB, Kemshead JT. A pilot study of monoclonal antibody targeted radiotherapy in the treatment of central nervous system leukaemia in children. Br J Haematol 1991;77:466-72.
8. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
9. Bourne S, Lashford LS, Garson J, Coakham HB, Kemshead JT. Monoclonal antibodies M340 and UJ181.4 recognise antigens associated with primitive neuroectodermal tumours/tissues. Hybridoma 1989;8:415-26.
10. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993;67:144-51.
11. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmuno-conjugates. Radiother Oncol 1995;34:121-31.
12. Medical Internal Radiation Dose Committee. MIRD dosimetry scheme. J Nucl Med 1971;12:1-32.
13. Berger JM. Distribution of absorbed dose around point sources of electrons and β-particles in water and other media. J Nucl Med 1971;7(Suppl. 5):18.
14. Snyder WS, Ford MR, Warner GG, Watson SB. "S", Absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: Society of Nuclear Medicine, 1975.
15. Ganong WF. Section VI. Circulation. In: Review of Medical Physiology. Los Altos, California: LANGE Medical Publications; 1985:421-527.
16. International Commission on Radiological protection. Report of Committee 2. Oxford: Pergamon Press, 1959.
17. White DR, Widdowson EM, Woodard HQ, Dickerson JWT. The composition of body tissue (11) fetus to young adult. Br J Radiol 1991;64:149-39.
18. Dillman LT, Von der Lage FC. Radionuclide decay schemes and nuclear parameters for use in radiation dose estimation, MIRD Pamphlet No. 10. New York: Society of Nuclear Medicine, 1975.
19. Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992;24:583-91.
20. Larson SM. Radioimmunology. Imaging and therapy. Cancer 1991;67:1253-60.
21. Perkins AC, Whalley DR, Ballantyne KC, Pimm MV. Gamma camera emission tomography using radiolabelled antibodies. Eur J Nucl Med. 1988;14:45-9.
22. Bigner DD, Brown M, Coleman E, Friedman AH, Friedman HS, McLendon RE, et al. Phase 1 studies of treatment of malignant gliomas and neoplastic meningitis with 131-I radiolabelled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulphate Mel-14 (Fab′) 2-a preliminary report. J Neuro Oncol 1995;24:109-22.
23. Sturiale C, Arista A, Lazzari S, Frattarelli M, Donati R, Sarti G, et al. Intralesional radioimmunotherapy of malignant gliomas: clinical experiences in recurrent and primary tumours. Tumour Targeting 1995;3:163-76.
24. 131I-monoclonal antibodies for the treatment of central nervous system malignancies. Int J Radiat Oncol Biol Phys 1995;31:541-52.